Incannex Healthcare (IXHL) said Wednesday it has completed patient dosing in the phase 2 portion of its phase 2/3 study of IHL-42X in obstructive sleep apnea.
Incannex shares rallied more than 700% in recent trading.
The company said it expects to conclude end-of-study follow-up assessments by May 17, with topline data anticipated in July.
Incannex also said it is preparing for a meeting with the US Food and Drug Administration ahead of the data readout to discuss results and steps toward a new drug application submission.
The company said phase 3 trial planning is underway and will be conducted at US sites to improve operational efficiency.
Incannex said it has started to engage in preliminary commercial discussions amid "growing interest" in the IHL-42X program.
Price: 0.74, Change: +0.66, Percent Change: +768.70
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。